Product logins

Find logins to all Clarivate products below.

home   •  Research Reports  •  Disease Landscape and Forecast Insights

Gastroesophageal Cancer | Unmet Need | US/EU | 2018

Login to access report north_east
Contact sales account_box

The genetic complexity and heterogeneity of gastric and GEJ adenocarcinoma poses a significant challenge for the development of treatment strategies for these cancers. Despite advancements in the treatment algorithm with the use of Keytruda (Merck & Co.) for metastatic gastric and GEJ adenocarcinoma tumors expressing PD-L1 and Herceptin (Roche/Genentech) for HER2-positive metastatic gastric or GEJ adenocarcinoma, therapeutic options for a large proportion of metastatic patients remain severely limited. Cyramza (Eli Lilly), with or without paclitaxel, is frequently prescribed for second- and subsequent-line treatment of metastatic gastric and GEJ adenocarcinoma. Cytotoxic monotherapies and doublet or triplet chemotherapy regimens remain a mainstay of treatment. The substantial unmet medical need for therapeutic management of metastatic gastric and GEJ adenocarcinoma with efficacious and well-tolerated novel therapies presents an attractive opportunity for drug developers.

QUESTIONS ANSWERED

  • What are the treatment drivers and goals for metastatic gastric and GEJ adenocarcinoma?
  • What attributes are key influencers, which have limited impact, and which are hidden opportunities for drug developers?
  • How do current therapies perform on key treatment drivers and goals for metastatic gastric and GEJ adenocarcinoma?
  • What are the prevailing areas of unmet need and opportunity in metastatic gastric and GEJ adenocarcinoma?

PRODUCT DESCRIPTION

Provides quantitative insight into U.S. and European physician perceptions of key treatment drivers and goals and the current level of unmet need for a specific disease. Commercial opportunities are analyzed and the extent to which emerging therapies may capitalize on these opportunities is evaluated.

Markets covered: United States, France, Germany, United Kingdom.

Primary research: Survey of 60 U.S. and 30 European medical oncologists fielded in June 2018.

Key companies: Roche/Genentech, Eli Lilly, Merck & Co.

Key drugs: Herceptin, Cyramza, Keytruda.

Contact sales account_box
Login to access report north_east

Related Market Assessment Reports

Report
Asthma – Current Treatment – Treatment Algorithms: Claims Data Analysis – Pediatric Asthma (US)
Pediatric asthma is treated using two types of pharmacotherapies: rescue therapy for acute symptoms via bronchodilation (e.g., a SABA such as Teva’s ProAir HFA) and maintenance therapy to prevent…
north_east
Report
Acute Coronary Syndrome – Unmet Need – Unmet Need – Acute Coronary Syndrome: Secondary Prevention, on Top of Statin Treatment (US/EU)
This report covers the 12-month post-hospital management of secondary prevention in ACS patients. Reducing cardiovascular (CV) residual risk and achieving guideline-recommended LDL-C targets…
north_east
Report
Beta Thalassemia – Landscape & Forecast – Niche & Rare Disease Landscape & Forecast (US/EU5)
Beta thalassemia (BT) is a rare genetic disorder characterized by the reduced production of hemoglobin. BT minor is caused by a mutation in one hemoglobin beta (HBB) gene, and transfusion-dependent…
north_east
Report
Multiple Sclerosis – Unmet Need – Unmet Need – Multiple Sclerosis: Nonrelapsing Secondary-Progressive Multiple Sclerosis (US/EU)
No treatments are approved for nonrelapsing secondary-progressive multiple sclerosis (nrSP-MS), an MS disease course in which physical disability accumulates in the absence of superimposed relapses…
north_east
Report
Osteoarthritic Pain – Current Treatment – Treatment Algorithms: Claims Data Analysis – Osteoarthritic Pain (US)
Osteoarthritic (OA) pain affects more than 30 million people in the United States, and the aging population and rising obesity rates are expected to drive further increases. Current treatments,…
north_east

Follow us

Contact us

Sales enquiries north_east
Customer service north_east
Support north_east